Neoadjuvant Immune Checkpoint Inhibitor Treatment in Urothelial Cancer

NCT04624399 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

58

Enrollment

OTHER

Sponsor class

Conditions

Urogenital Cancer

Interventions

DRUG: Atezolizumab

Sponsor

Queen Mary University of London

Collaborators

[object Object]